MA-EXAGRID
28.5.2019 17:41:10 CEST | Business Wire | Press release
ExaGrid ® , a leading provider of intelligent hyperconverged storage for backup, today announced that Physicians’ Reciprocal Insurers (PRI) uses ExaGrid disk-based backup systems to significantly increase data protection with secure backups.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190528005580/en/
PRI is a leading provider of professional liability insurance for physicians and medical facilities. As the second largest medical malpractice insurer in New York State and one of the top ten in the U.S., PRI is recognized as one of the most respected names in its field.
PRI replaced its previous system with ExaGrid and Veeam after its IT staff spent too much time troubleshooting backup issues. Al Villani, PRI’s senior system administrator said, “Veritas NetBackup wasn’t set up to send us any kind of alerts if there was an issue, so we had to log in and look through it, which was a lot of manual work. Our calls to Symantec support were sent offshore right away, and by the time they got back to us, we had usually found the solution by searching online. Veritas eventually reacquired NetBackup, but the support never improved.”
ExaGrid solved backup issues PRI had struggled with, including:
- Storage capacity issues
- Backups that exceeded window, slowing company-wide systems during workday
- Time-consuming backup management
- Complicated offsite storage
The security of data storage in the insurance industry has been moving toward stricter regulation, so PRI looked for a solution that would help keep the company ahead of the curve. “The insurance claims we process contain sensitive information, such as birth dates and Social Security numbers—even the tape we used was encrypted, the cases we stored them in were locked, and Iron Mountain had to sign for them—the state regulations are pretty thorough when it comes to security. Many solutions don’t offer encryption or the ability to encrypt at rest like ExaGrid does,” said Villani.
A major issue that PRI faced was that its backups took days and slowed the entire system down, impacting workflow. “Our weekly full backup used to run from Saturday morning at 2:00 a.m. all the way into Tuesday afternoon. Every Monday, users would be calling in and asking why the system was so slow. Now, our weekly full takes just three hours! We thought something was broken the first time we used ExaGrid, so we called our support engineer who confirmed that everything ran correctly. It’s totally incredible! Working with our [ExaGrid] support engineer has been a saving grace. Managing backups had been a nightmare at times, but switching to ExaGrid has been a dream come true. We’re saving about 25-30 hours a week on managing backups. The ExaGrid system doesn’t need a lot of babysitting, and our support engineer is available whenever we need help with any issue.”
As an insurance company, PRI has a complex retention policy for its data. “We keep five weeks of daily backups, eight weeks of weekly backups, a year’s worth of monthly backups onsite, and one yearly onsite with seven yearlies offsite, as well as offsite storage for infinite fiscals and monthly backups,” said Villani. “We were skeptical at first that an ExaGrid system could handle that amount of storage, but the engineers sized everything really well and ExaGrid guaranteed the sizing would work for two years, and that if we needed to add another appliance, they would supply it. Seeing that in writing was pretty impressive!”
Read the complete PRI customer success story to learn more about the company’s experience using ExaGrid.
ExaGrid’s published customer success stories and enterprise stories number over 360, more than all other vendors in the space combined. These stories demonstrate how satisfied customers are with ExaGrid’s unique architectural approach, differentiated product, and unrivalled customer support. Customers consistently state that not only is the product best-in-class, but ‘it just works.’
About ExaGrid
ExaGrid provides intelligent hyperconverged
storage for backup with data deduplication, a unique landing zone, and
scale-out architecture. ExaGrid’s landing zone provides for the fastest
backups, restores, and instant VM recoveries. Its scale-out architecture
includes full appliances in a scale-out system and ensures a
fixed-length backup window as data grows, eliminating expensive forklift
upgrades. Visit us at exagrid.com
or
connect with us on LinkedIn
.
See what our customers have to say about their own ExaGrid experiences
and why they now spend significantly less time on backup.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190528005580/en/
Contact:
Stacey Foster ExaGrid sfoster@exagrid.com 508-898-2872 x0248
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
